CXCR5 polymorphisms in non-Hodgkin lymphoma risk and prognosis

Cancer Immunology, Immunotherapy

Volumn 62, Issue 9, 2013, Pages 1475-1484

  Charbonneau, Bridget ^a   Wang, Alice H ^a   Maurer, Matthew J ^a   Asmann, Yan W ^a   Zent, Clive S ^b   Link, Brian K ^c   Ansell, Stephen M ^b   Weiner, George J ^c   Ozsan, Nazan ^d   Feldman, Andrew L ^b   Witzig, Thomas E ^b   Cunningham, Julie M ^b   Dogan, Ahmet ^b   Habermann, Thomas M ^b   Slager, Susan L ^a   Novak, Anne J ^b   Cerhan, James R ^a  

^a Mayo Clinic College of Medicine   (United States)

^b MAYO CLINIC   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d EGE UNIVERSITY   (Turkey)

Author keywords

Case control; Non Hodgkin lymphoma; Prognosis; Prospective cohort; SNPs

Indexed keywords

CHEMOKINE RECEPTOR CXCR5; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADULT; ALLELE; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; CARCINOGENESIS; CELL FUNCTION; CHRONIC LYMPHATIC LEUKEMIA; CONTROLLED STUDY; CXCR5 GENE; EVENT FREE SURVIVAL; FEMALE; FOLLICULAR LYMPHOMA; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; GERM LINE; HUMAN; HUMAN CELL; LARGE CELL LYMPHOMA; LYMPHOCYTOMA; MAJOR CLINICAL STUDY; MALE; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; NONHODGKIN LYMPHOMA; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM;

CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HUMANS; LYMPHOMA, NON-HODGKIN; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; PROGNOSIS; RECEPTORS, CXCR5; RISK FACTORS;

EID: 84883464014     PISSN: 03407004     EISSN: 14320851     Source Type: Journal    
DOI: 10.1007/s00262-013-1452-4     Document Type: Article

References (42)

1. Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62(1):10-29. doi: 10.3322/caac.20138
2. Morton LM, Wang SS, Cozen W, Linet MS, Chatterjee N, Davis S, Severson RK, Colt JS, Vasef MA, Rothman N, Blair A, Bernstein L, Cross AJ, De Roos AJ, Engels EA, Hein DW, Hill DA, Kelemen LE, Lim U, Lynch CF, Schenk M, Wacholder S, Ward MH, Hoar Zahm S, Chanock SJ, Cerhan JR, Hartge P (2008) Etiologic heterogeneity among non-Hodgkin lymphoma subtypes. Blood 112(13):5150-5160. doi: 10.1182/blood-2008-01-133587
3. Forster R, Mattis AE, Kremmer E, Wolf E, Brem G, Lipp M (1996) A putative chemokine receptor, BLR1, directs B cell migration to defined lymphoid organs and specific anatomic compartments of the spleen. Cell 87(6):1037-1047
4. Ansel KM, Ngo VN, Hyman PL, Luther SA, Forster R, Sedgwick JD, Browning JL, Lipp M, Cyster JG (2000) A chemokine-driven positive feedback loop organizes lymphoid follicles. Nature 406(6793):309-314. doi: 10.1038/35018581
5. Kurtova AV, Tamayo AT, Ford RJ, Burger JA (2009) Mantle cell lymphoma cells express high levels of CXCR4, CXCR5, and VLA-4 (CD49d): importance for interactions with the stromal microenvironment and specific targeting. Blood 113(19):4604-4613. doi: 10.1182/blood-2008-10-185827
6. Krenacs L, Schaerli P, Kis G, Bagdi E (2006) Phenotype of neoplastic cells in angioimmunoblastic T-cell lymphoma is consistent with activated follicular B helper T cells. Blood 108(3):1110-1111. doi: 10.1182/blood-2006-01- 0394
7. Deutsch AJ, Aigelsreiter A, Steinbauer E, Fruhwirth M, Kerl H, Beham-Schmid C, Schaider H, Neumeister P (2008) Distinct signatures of B-cell homeostatic and activation-dependent chemokine receptors in the development and progression of extragastric MALT lymphomas. J Pathol 215(4):431-444. doi: 10.1002/path.2372
8. Machado L, Jarrett R, Morgan S, Murray P, Hunter B, Hamilton E, Crocker J, Thomas W, Steven N, Ismail T, Chapman A, Adams DH, Lee SP (2009) Expression and function of T cell homing molecules in Hodgkin's lymphoma. Cancer Immunol Immunother 58(1):85-94. doi: 10.1007/s00262-008-0528-z
9. Song H, Tong D, Cha Z, Bai J (2012) C-X-C chemokine receptor type 5 gene polymorphisms are associated with non-Hodgkin lymphoma. Mol Biol Rep. doi: 10.1007/s11033-012-1717-6
10. Mells GF, Floyd JA, Morley KI, Cordell HJ, Franklin CS, Shin SY, Heneghan MA, Neuberger JM, Donaldson PT, Day DB, Ducker SJ, Muriithi AW, Wheater EF, Hammond CJ, Dawwas MF, Jones DE, Peltonen L, Alexander GJ, Sandford RN, Anderson CA (2011) Genome-wide association study identifies 12 new susceptibility loci for primary biliary cirrhosis. Nat Genet 43(4):329-332. doi: 10.1038/ng.789
11. Sawcer S, Hellenthal G, Pirinen M, Spencer CC, Patsopoulos NA, Moutsianas L, Dilthey A, Su Z, Freeman C, Hunt SE, Edkins S, Gray E, Booth DR, Potter SC, Goris A, Band G, Oturai AB, Strange A, Saarela J, Bellenguez C, Fontaine B, Gillman M, Hemmer B, Gwilliam R, Zipp F, Jayakumar A, Martin R, Leslie S, Hawkins S, Giannoulatou E, D'Alfonso S, Blackburn H, Martinelli Boneschi F, Liddle J, Harbo HF, Perez ML, Spurkland A, Waller MJ, Mycko MP, Ricketts M, Comabella M, Hammond N, Kockum I, McCann OT, Ban M, Whittaker P, Kemppinen A, Weston P, Hawkins C, Widaa S, Zajicek J, Dronov S, Robertson N, Bumpstead SJ, Barcellos LF, Ravindrarajah R, Abraham R, Alfredsson L, Ardlie K, Aubin C, Baker A, Baker K, Baranzini SE, Bergamaschi L, Bergamaschi R, Bernstein A, Berthele A, Boggild M, Bradfield JP, Brassat D, Broadley SA, Buck D, Butzkueven H, Capra R, Carroll WM, Cavalla P, Celius EG, Cepok S, Chiavacci R, Clerget-Darpoux F, Clysters K, Comi G, Cossburn M, Cournu-Rebeix I, Cox MB, Cozen W, Cree BA, Cross AH, Cusi D, Daly MJ, Davis E, de Bakker PI, Debouverie M, D'Hooghe M B, Dixon K, Dobosi R, Dubois B, Ellinghaus D, Elovaara I, Esposito F, Fontenille C, Foote S, Franke A, Galimberti D, Ghezzi A, Glessner J, Gomez R, Gout O, Graham C, Grant SF, Guerini FR, Hakonarson H, Hall P, Hamsten A, Hartung HP, Heard RN, Heath S, Hobart J, Hoshi M, Infante-Duarte C, Ingram G, Ingram W, Islam T, Jagodic M, Kabesch M, Kermode AG, Kilpatrick TJ, Kim C, Klopp N, Koivisto K, Larsson M, Lathrop M, Lechner-Scott JS, Leone MA, Leppa V, Liljedahl U, Bomfim IL, Lincoln RR, Link J, Liu J, Lorentzen AR, Lupoli S, Macciardi F, Mack T, Marriott M, Martinelli V, Mason D, McCauley JL, Mentch F, Mero IL, Mihalova T, Montalban X, Mottershead J, Myhr KM, Naldi P, Ollier W, Page A, Palotie A, Pelletier J, Piccio L, Pickersgill T, Piehl F, Pobywajlo S, Quach HL, Ramsay PP, Reunanen M, Reynolds R, Rioux JD, Rodegher M, Roesner S, Rubio JP, Ruckert IM, Salvetti M, Salvi E, Santaniello A, Schaefer CA, Schreiber S, Schulze C, Scott RJ, Sellebjerg F, Selmaj KW, Sexton D, Shen L, Simms-Acuna B, Skidmore S, Sleiman PM, Smestad C, Sorensen PS, Sondergaard HB, Stankovich J, Strange RC, Sulonen AM, Sundqvist E, Syvanen AC, Taddeo F, Taylor B, Blackwell JM, Tienari P, Bramon E, Tourbah A, Brown MA, Tronczynska E, Casas JP, Tubridy N, Corvin A, Vickery J, Jankowski J, Villoslada P, Markus HS, Wang K, Mathew CG, Wason J, Palmer CN, Wichmann HE, Plomin R, Willoughby E, Rautanen A, Winkelmann J, Wittig M, Trembath RC, Yaouanq J, Viswanathan AC, Zhang H, Wood NW, Zuvich R, Deloukas P, Langford C, Duncanson A, Oksenberg JR, Pericak-Vance MA, Haines JL, Olsson T, Hillert J, Ivinson AJ, De Jager PL, Peltonen L, Stewart GJ, Hafler DA, Hauser SL, McVean G, Donnelly P, Compston A (2011) Genetic risk and a primary role for cell-mediated immune mechanisms in multiple sclerosis. Nature 476(7359):214-219. doi: 10.1038/nature10251
12. Cerhan JR, Fredericksen ZS, Wang AH, Habermann TM, Kay NE, Macon WR, Cunningham JM, Shanafelt TD, Ansell SM, Call TG, Witzig TE, Slager SL, Liebow M (2011) Design and validity of a clinic-based case-control study on the molecular epidemiology of lymphoma. Int J Mol Epidemiol Genet 2(2):95-113
13. Jaffe ES, Harris NL, Stein H, Vardiman JW (2001) World Health Organization classification of tumours: pathology and genetics, tumours of haematopoietic and lymphoid tissues. IARC Press, Lyon
14. Campo E, Swerdlow SH, Harris NL, Pileri S, Stein H, Jaffe ES (2011) The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications. Blood 117(19):5019-5032. doi: 10.1182/blood-2011-01- 293050
15. Hans CP, Weisenburger DD, Greiner TC, Gascoyne RD, Delabie J, Ott G, Muller-Hermelink HK, Campo E, Braziel RM, Jaffe ES, Pan Z, Farinha P, Smith LM, Falini B, Banham AH, Rosenwald A, Staudt LM, Connors JM, Armitage JO, Chan WC (2004) Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood 103(1):275-282. doi: 10.1182/blood-2003-05-1545
16. Drake MT, Maurer MJ, Link BK, Habermann TM, Ansell SM, Micallef IN, Kelly JL, Macon WR, Nowakowski GS, Inwards DJ, Johnston PB, Singh RJ, Allmer C, Slager SL, Weiner GJ, Witzig TE, Cerhan JR (2010) Vitamin D insufficiency and prognosis in non-Hodgkin's lymphoma. J Clin Oncol 28(27):4191-4198. doi: 10.1200/JCO.2010.28.6674
17. Link BK, Maurer MJ, Nowakowski GS, Ansell SM, Macon WR, Syrbu SI, Slager SL, Thompson CA, Inwards DJ, Johnston PB, Colgan JP, Witzig TE, Habermann TM, Cerhan JR (2013) Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy Era: a report from the University of Iowa/Mayo Clinic SPORE molecular epidemiology resource. J Clin Oncol (in press)
18. Lossos IS, Gascoyne RD (2011) Transformation of follicular lymphoma. Best Pract Res Clin Haematol 24(2):147-163. doi: 10.1016/j.beha.2011.02.006
19. Al-Tourah AJ, Gill KK, Chhanabhai M, Hoskins PJ, Klasa RJ, Savage KJ, Sehn LH, Shenkier TN, Gascoyne RD, Connors JM (2008) Population-based analysis of incidence and outcome of transformed non-Hodgkin's lymphoma. J Clin Oncol 26(32):5165-5169. doi: 10.1200/JCO.2008.16.0283
20. The International Non-Hodgkin's Lymphoma Prognostic Factors Project (1993) A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 329(14):987-994. doi: 10.1056/NEJM199309303291402
21. Solal-Celigny P, Roy P, Colombat P, White J, Armitage JO, Arranz-Saez R, Au WY, Bellei M, Brice P, Caballero D, Coiffier B, Conde-Garcia E, Doyen C, Federico M, Fisher RI, Garcia-Conde JF, Guglielmi C, Hagenbeek A, Haioun C, LeBlanc M, Lister AT, Lopez-Guillermo A, McLaughlin P, Milpied N, Morel P, Mounier N, Proctor SJ, Rohatiner A, Smith P, Soubeyran P, Tilly H, Vitolo U, Zinzani PL, Zucca E, Montserrat E (2004) Follicular lymphoma international prognostic index. Blood 104(5):1258-1265. doi: 10.1182/blood-2003-12-4434
22. Hoster E, Dreyling M, Klapper W, Gisselbrecht C, van Hoof A, Kluin-Nelemans HC, Pfreundschuh M, Reiser M, Metzner B, Einsele H, Peter N, Jung W, Wormann B, Ludwig WD, Duhrsen U, Eimermacher H, Wandt H, Hasford J, Hiddemann W, Unterhalt M (2008) A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood 111(2):558-565. doi: 10.1182/blood-2007-06-095331
23. Ziebarth JD, Bhattacharya A, Chen A, Cui Y (2012) PolymiRTS Database 2.0: linking polymorphisms in microRNA target sites with human diseases and complex traits. Nucleic Acids Res 40(Database issue):D216-D221. doi: 10.1093/nar/gkr1026
24. Ward LD, Kellis M (2012) HaploReg: a resource for exploring chromatin states, conservation, and regulatory motif alterations within sets of genetically linked variants. Nucleic Acids Res 40(Database issue):D930-D934. doi: 10.1093/nar/gkr917
25. Nogai H, Dorken B, Lenz G (2011) Pathogenesis of non-Hodgkin's lymphoma. J Clin Oncol 29(14):1803-1811. doi: 10.1200/JCO.2010.33.3252
26. Muller G, Hopken UE, Lipp M (2003) The impact of CCR7 and CXCR5 on lymphoid organ development and systemic immunity. Immunol Rev 195:117-135
27. Saez de Guinoa J, Barrio L, Mellado M, Carrasco YR (2011) CXCL13/CXCR5 signaling enhances BCR-triggered B-cell activation by shaping cell dynamics. Blood 118(6):1560-1569. doi: 10.1182/blood-2011-01-332106
28. Widney DP, Gui D, Popoviciu LM, Said JW, Breen EC, Huang X, Kitchen CM, Alcantar JM, Smith JB, Detels R, Martinez-Maza O (2010) Expression and function of the Chemokine, CXCL13, and Its Receptor, CXCR5, in Aids-Associated Non-Hodgkin's Lymphoma. AIDS Res Treat 2010:164586. doi: 10.1155/2010/164586
29. Hussain S, Zhu W, Chang SC, Crabb Breen E, Vendrame E, Magpantay L, Widney D, Conn D, Sehl ME, Jacobson L, Bream J, Wolinsky S, Rinaldo C Jr, Ambinder R, Detels R, Zhang ZF, Martinez-Maza O (2012) Serum levels of the chemokine CXCL13, genetic variation in CXCL13 and its receptor CXCR5, and HIV-associated non-Hodgkin B cell lymphoma risk. Cancer Epidemiol Biomarkers Prev. doi: 10.1158/1055-9965.EPI-12-1122
30. De Roos AJ, Mirick DK, Edlefsen KL, LaCroix AZ, Kopecky KJ, Madeleine MM, Magpantay L, Martinez-Maza O (2012) Markers of B-cell activation in relation to risk of non-Hodgkin lymphoma. Cancer Res 72(18):4733-4743. doi: 10.1158/0008-5472.CAN-12-1639
31. Burkle A, Niedermeier M, Schmitt-Graff A, Wierda WG, Keating MJ, Burger JA (2007) Overexpression of the CXCR5 chemokine receptor, and its ligand, CXCL13 in B-cell chronic lymphocytic leukemia. Blood 110(9):3316-3325. doi: 10.1182/blood-2007-05-089409
32. Xia Z, Dickens M, Raingeaud J, Davis RJ, Greenberg ME (1995) Opposing effects of ERK and JNK-p38 MAP kinases on apoptosis. Science 270(5240):1326-1331
33. Vineis P, Crosignani P, Vigano C, Fontana A, Masala G, Stagnaro E, Miligi L, Costantini AS, Nanni O, Ramazzotti V, Rodella S, Tumino R, Vindigni C (2001) Lymphomas and multiple sclerosis in a multicenter case-control study. Epidemiology 12(1):134-135
34. Zhang Y, Holford TR, Leaderer B, Zahm SH, Boyle P, Morton LM, Zhang B, Zou K, Flynn S, Tallini G, Owens PH, Zheng T (2004) Prior medical conditions and medication use and risk of non-Hodgkin lymphoma in Connecticut United States women. Cancer Causes Control: CCC 15(4):419-428. doi: 10.1023/B:CACO.0000027506. 55846.5d
35. Ekstrom Smedby K, Vajdic CM, Falster M, Engels EA, Martinez-Maza O, Turner J, Hjalgrim H, Vineis P, Seniori Costantini A, Bracci PM, Holly EA, Willett E, Spinelli JJ, La Vecchia C, Zheng T, Becker N, De Sanjose S, Chiu BC, Dal Maso L, Cocco P, Maynadie M, Foretova L, Staines A, Brennan P, Davis S, Severson R, Cerhan JR, Breen EC, Birmann B, Grulich AE, Cozen W (2008) Autoimmune disorders and risk of non-Hodgkin lymphoma subtypes: a pooled analysis within the InterLymph Consortium. Blood 111(8):4029-4038. doi: 10.1182/blood-2007-10-119974
36. Koshiol J, Lam TK, Gridley G, Check D, Brown LM, Landgren O (2011) Racial differences in chronic immune stimulatory conditions and risk of non-Hodgkin's lymphoma in veterans from the United States. J Clin Oncol 29(4):378-385. doi: 10.1200/JCO.2010.30.1515
37. Krumbholz M, Derfuss T, Hohlfeld R, Meinl E (2012) B cells and antibodies in multiple sclerosis pathogenesis and therapy. Nat Rev Neurol 8(11):613-623. doi: 10.1038/nrneurol.2012.203
38. Schreiber RD, Old LJ, Smyth MJ (2011) Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331(6024):1565-1570. doi: 10.1126/science.1203486
39. Sauna ZE, Kimchi-Sarfaty C (2011) Understanding the contribution of synonymous mutations to human disease. Nat Rev Genet 12(10):683-691. doi: 10.1038/nrg3051
40. Katoh M (2003) Identification and characterization of human BCL9L gene and mouse Bcl9 l gene in silico. Int J Mol Med 12(4):643-649
41. Willis TG, Zalcberg IR, Coignet LJ, Wlodarska I, Stul M, Jadayel DM, Bastard C, Treleaven JG, Catovsky D, Silva ML, Dyer MJ (1998) Molecular cloning of translocation t(1;14)(q21;q32) defines a novel gene (BCL9) at chromosome 1q21. Blood 91(6):1873-1881
42. Brembeck FH, Wiese M, Zatula N, Grigoryan T, Dai Y, Fritzmann J, Birchmeier W (2011) BCL9-2 promotes early stages of intestinal tumor progression. Gastroenterology 141(4):1359-1370, 1370:e1351-e1353. doi: 10.1053/j.gastro.2011.06.039